Spyre Therapeutics CFO Executes Rule 10b5-1 Stock Sale and Option Exercise
Scott L. Burrows, the Chief Financial Officer of Spyre Therapeutics, Inc. (NASDAQ: SYRE), has completed a series of insider transactions involving both the sale of common stock and the exercise of stock options. On May 1, 2026, Mr. Burrows sold 12,500 shares at a price of $71.37 per share, resulting in total proceeds of $892,125. This divestment oc…